New Horizons in the Treatment and Management of Metastatic Colorectal Cancer (mCRC): Best Practices for Improved Patient Outcomes


New Horizons in the Treatment and Management of Metastatic Colorectal Cancer (mCRC):
Best Practices for Improved Patient Outcomes is a 5-part webcast series that will provide
attendees with the latest information in mCRC Management.
 

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 5 or in order.

These are archives of live webinars held between July 19, 2017 and Aug 16, 2017.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session has its own specific valid dates

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the “download” button and either print or save.

 

This series is supported by educational grants from Bayer Healthcare and Merck Sharp & Dohme Corp

 

Description: Colorectal cancer (CRC) is the development of cancer from the colon or rectum, due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. In 2017, it is expected that there will be 134,490 new cases of colorectal cancer and 49,190 deaths. When discovered early, CRC is highly treatable. However, when the disease has spread, or metastasized, treatment and management becomes much more difficult. Fortunately, targeted- and immuno-therapy options have become available for patients with metastatic colorectal cancer (mCRC), giving clinicians and managed care professionals more options in managing this patient population. This five part webinar series will look closely at personalizing therapy with VEGF- and EGFR-targeted agents and novel immunotherapeutic options to meet a patient's need in mCRC, novel options for MSI-positive mCRC, guidelines and strategies for managing later lines of therapy and sequencing, the role of biomarkers in guiding treatment in mCRC, and strategies for managing adverse events associated with targeted therapies and immunotherapies in mCRC.

 

This multi-part program on new horizons in the treatment and management of metastatic colorectal cancer will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Attendees will be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients.


VEGF- and EGFR-Targeted Agents in Metastatic Colorectal Cancer (mCRC): Personalizing Therapy to Meet a Patient's Needs 

1. Analyze the rationale and role of VEGF- and EGFR-targeted agents in the treatment of metastatic colorectal cancer (mCRC), especially in later lines of therapy

2. Integrate clinical data and guideline recommendations into decisions about the optimal use of VEGF- and EGFR-directed therapy in treatment protocols for patients with mCRC

3. Individualize treatment with VEGF- and EGFR-targeted agents based on patient factors including including tumor characteristics, treatment history, common adverse effects, and age for optimal care

4. Discuss methods to enable optimal cost management of targeted therapies in mCRC

Physician, Nursing and CMCN credits valid to September 30, 2018
 

Integration of Novel Immunotherapies into the Paradigm of MSI-positive mCRC

1. Discuss the role of immunotherapies in the treatment of MSI-positive mCRC

2. Review recent clinical data on immunotherapy in the management of MSI-positive mCRC

3. Individualize treatment with immunotherapeutic agents based on patient factors including including tumor characteristics, treatment history, common adverse effects, and age for optimal care

4. Assess key sequencing considerations when formulating a plan for individualized treatment in MSI-positive mCRC

Physician, Nursing and CMCN credits valid to September 30, 2018
 

Treatment Lines and Sequencing in mCRC: Best Practices Beyond First-Line Therapy

1. Discuss challenges associated with disease progression in mCRC and strategies for managing therapy beyond the first line

2. Analyze the relative benefits and limitations of current therapy for mCRC in later lines of therapy

3. Explore the role of VEGF- and EGFR-targeted agents in later lines of therapy in mCRC

4. Explore the role of immunotherapeutic agents in beyond first-line therapy in mCRC

5. Assess key sequencing considerations when formulating a plan for MSI-positive mCRC

Physician, Nursing and CMCN credits valid to September 30, 2018
 

Understanding the Role of Biomarkers in the Management of mCRC: What Can They Tell Us?

1. Examine the role and use of biomarkers and molecular testing to guide treatment selection for patients with mCRC

2. Review RAS, MSI-H and BRAF biomarkers in mCRC and what it means for treatment and management decisions

3. Discuss the role of the pathologist, pharmacists, payer and clinician in biomarker testing and treatment guidance

Physician, Nursing and CMCN credits valid to September 30, 2018
 

Strategies for Managing Adverse Events Associated with Targeted Therapies and Immunotherapies in mCRC: Improving Patient Adherence and Quality of Life

1. Identify adverse events commonly associated with targeted agents used in the treatment of metastatic colorectal cancer (mCRC)

2. Identify adverse events commonly associated with immunotherapeutic agents used in the treatment of metastatic colorectal cancer (mCRC)

3. Discuss strategies to mitigate side effects related to treatment with VEGF- and EGFR-targeted therapies and immunotherapeutic agents in patients with mCRC

4. Assess the informational needs of patients and families/caregivers regarding their treatment plan and identify methods to counsel them

5. Review how treatment strategies can be affected by adverse events based on patient’s individualized needs

Physician, Nursing and CMCN credits valid to September 30, 2018